Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis

TORRANCE, Calif.--(BUSINESS WIRE) October 26, 2020 -- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials